Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of sustained-release bimatoprost versus timolol in open-angle glaucoma or ocular hypertension
MOH_2017-03-20_000261Phase 3Recruiting
- Sponsor
- Allergan
- Start
- Dec 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bimatoprost and timolol in open-angle glaucoma (OAG) and ocular hypertension (3 arms), sponsored by Allergan. Started Dec 2014; status: recruiting.
02
Drugs
bimatoprosttimolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on MOH_2017-03-20_000261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-20_000261.